Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memo Therapeutics AG Identifies Potent SARS-CoV-2-Neutralizing Antibodies From the Blood of Recovered COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Memo Therapeutics"},{"company":"Spexis","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"Spexis Achieves First CARB-X Milestone for Its Thanatin Derivatives Program and Receives Funding of up to USD 1.9 Million to Initiate Lead Optimization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Spexis"}]

Spexis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Spexis Achieves First CARB-X Milestone for Its Thanatin Derivatives Program and Receives Funding of up to USD 1.9 Million to Initiate Lead Optimization

Details:

The award will support the continuation of the "thanatin derivatives program" including POL7306, belonging to Spexis' novel Outer Membrane Protein Targeting Antibiotic class of antibiotics to potentially treat life-threatening infections.

Lead Product(s): POL7306

Therapeutic Area: Infections and Infectious Diseases Product Name: POL7306

Highest Development Status: Discovery Product Type: Peptide

Partner/Sponsor/Collaborator: CARB-X

Deal Size: $1.9 million Upfront Cash: Undisclosed

Deal Type: Funding March 03, 2022

ASK
US

Upload
your Pipeline Activity

Memo Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Memo Therapeutics AG Identifies Potent SARS-CoV-2-Neutralizing Antibodies From the Blood of Recovered COVID-19 Patients

Details:

MTx’s DROPZYLLA® platform isolated ultra-rare and highly potent virus-neutralizing antibodies from COVID-19 patients within six weeks.

Lead Product(s): SARS-CoV-2-neutralizing antibodies

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY